For research purposes only — These compounds aren't FDA approved. All data presented is from clinical trials for educational reference.
KLOW
Regenerative Peptide Blend
Dosage
Quantity
Price
$116.99
Free shipping on orders $150+
60-day money-back guarantee
Secure checkout
Made in the USA
Certificate of Analysis
Batch verified lab data
99.93%
Purity
- Variant
- KLOW 80mg (10+10+50+10)
- Lot #
- A0112
- Labeled
- 20mg
- Actual
- 22.56mg
- Tested
- Feb 4, 2026
Frequently Researched Together
View allResearch Purposes Snapshot
KLOW combines BPC-157, TB-500, GHK-Cu, and KPV (α-MSH–derived tripeptide). Below aggregates what is commonly cited for each ingredient alone; this exact four-way blend is not backed by large dedicated human trials. Not FDA approved.
4
Pathways
VEGF / angiogenesis, actin motility, collagen–ECM programs, and NF-κB–linked inflammation control.
7×
GHR upregulation
BPC-157-associated growth hormone receptor induction by day 3 in tendon fibroblast reports.
70%
Collagen signal
GHK-Cu collagen synthesis increases vs controls in skin-focused preclinical summaries.
NF-κB
Inflammation brake
KPV is discussed as a nanomolar NF-κB / cytokine modulator via PepT1-relevant transport biology.
600+
Combined studies
Rough aggregate of indexed work across all four moieties (counts vary by database and filters).
Why four peptides together
Regeneration with inflammatory control
Each peptide is framed against a different repair phase while KPV adds NF-κB–biased anti-inflammatory control. BPC-157 is tied to perfusion and fibroblast support; TB-500 to actin-driven migration; GHK-Cu to matrix genes and collagen; KPV to shutting down excessive cytokine signaling that can stall resolution.
- GLOW (BPC + TB + Cu)Three regenerative pathway narratives
- KPV aloneNF-κB / cytokine axis emphasis
- KLOW (all four)Repair stack + inflammation governance
Research status
Where each moiety stands
- BPC-157 studies
- 200+ publications
- TB-500 studies
- 170+ publications
- GHK-Cu studies
- 130+ publications
- KPV studies
- 100+ publications
- Four-way combination
- Emerging / mechanistic only
Multi-study lens
600+ publications (aggregate)
4 pathway families in one stack
Fold-change from tendon fibroblast reports—not a percentage bar.
Gastroenterology literature often frames KPV uptake via PepT1 (e.g., Dalmasso et al., 2008).
Component findings
Individual peptide highlights
Research applications
Preclinical themes cited across the four moieties
Gut health
KPV is discussed for intestinal inflammation with PepT1-mediated uptake accentuated in IBD-like models.
Dalmasso et al., 2008
Skin regeneration
GHK-Cu collagen programs plus BPC-157 / TB-500 epithelial repair narratives; KPV adds cytokine control angles.
Pickart & Margolina, 2018
Tissue repair
TB-500 actin remodeling, BPC-157 fibroblast viability, GHK-Cu vascular stabilization, KPV inflammation damping.
Chi et al., 2017
Anti-inflammatory
KPV on NF-κB; BPC-157 on NO pathways; TB-500 on macrophage phenotypes; GHK-Cu on TNF-α in some reports.
Luger et al., 2007
KPV — NF-κB pathway modulation
C-terminal α-MSH tripeptide retaining anti-inflammatory potency: nanomolar NF-κB modulation, IL-8 / TNF-α decreases, and shortened inflammatory signaling in multiple models. Transport is linked to PepT1 rather than classical melanocortin receptors.
- NF-κB: active at nanomolar concentrations in cited work
- IL-8: dose-dependent reductions
- Uptake: PepT1-mediated transport narrative
- IBD context: PepT1 upregulation may enhance peptide delivery
Gastroenterology 2008 cluster (Dalmasso et al.)
Intestinal inflammation research
KLOW stacks BPC-157 GI-protective narratives with KPV's targeted anti-inflammatory readouts. Oral KPV in colitis models is tied to improved weight curves and histology; PepT1 upregulation during inflammation is framed as improved targeting.
Dalmasso et al., 2008
Skin & aesthetic research
Preclinical skin models discuss dermal remodeling, wound closure, barrier repair, and inflammatory dermatoses. GHK-Cu supports collagen synthesis; BPC-157 and TB-500 support epithelial kinetics; KPV contributes NF-κB-linked control.
- Collagen synthesis ↑ ~70% (GHK-Cu summaries)
- Gene-expression breadth: 4,000+ transcripts in GHK-Cu reviews
- Inflammation: KPV NF-κB angle
- Models: contact dermatitis, excisional wounds (literature-dependent)
GHK-Cu skin research compendia
Muscle & tendon repair
Soft-tissue injury literature emphasizes regeneration plus inflammation resolution—KPV is positioned to limit chronic inflammatory braking on remodeling.
Seiwerth et al., 2018
Safety profile from research
Preclinical narratives for each component
Ingredients are usually described as individually tolerable in animal work (BPC-157 acute tox packages, TB-500 rodent data, cosmetic GHK-Cu history, small KPV peptides). Combined four-peptide safety is not established.
Commonly cited mild events
Injection site reactions
MildNo systemic toxicity (preclinical summaries)
MildKPV — favorable small-peptide profile
MildDiscontinuation / tox themes
- BPC-157No classical LD50 in cited rodent packages
- TB-500Well tolerated in animal tox files
- GHK-CuLong cosmetic-use track record (formulation-dependent)
- KPVNaturally occurring fragment; low immunogenicity narrative
- Individual profiles look manageable in archives—human RCT depth remains thin.
- KPV's endogenous origin is often cited for tolerability, not invulnerability.
- Blend characterization still needs dedicated tox / PK packages.
Trial-style exclusions
- BPC-157 / TB-500: investigational; sport-governed bans apply.
- GHK-Cu: cosmetic ingredient with parallel lab research streams.
- KPV: research peptide; endogenous fragment framing does not equal approval.
- No FDA approval for any listed therapeutic indication for this SKU.
Storage handling reference
Peptide handling
Cold
Lyophilized: refrigerate/freeze per COA.
Reconstitution
Sterile technique; multi-peptide SOPs.
Light
Minimize UV during prep.
Aliquot
Limit freeze-thaw across four actives.
Researcher notes
- All four moieties are research-grade with mixed regulatory histories—treat compliance as SKU-specific.
- GHK-Cu carries the longest consumer-adjacent safety narrative via cosmetics; still not a drug approval.
- KPV benefits from endogenous-sequence language but still needs formal characterization in your stack.
- Any synergy statement is mechanistic until four-way GLP tox and clinical data exist.
Important Research Notice
Not for human consumption. This product and all products are sold exclusively for research and educational purposes. It is not intended to diagnose, treat, cure, or prevent any disease.
All clinical trial data and research findings presented on this page are sourced from journals and official publications but should be fact checked. They are provided for educational reference only and should not be interpreted as medical advice or product claims.
By purchasing this product, you confirm that you are a qualified researcher and will use it in accordance with all applicable laws and regulations and you do not intend to use it for human consumption.